Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/5/2025

Management of Erythrocytosis in HHT Patients

Understanding the Condition

  • The American Society of Hematology notes that erythrocytosis in HHT patients is exceedingly rare and should prompt immediate investigation for alternative causes, as the overwhelming majority of HHT patients present with anemia from chronic bleeding rather than elevated red blood cell counts 1, 2
  • Approximately 50% of HHT patients experience iron deficiency anemia from chronic bleeding, making anemia the typical presentation rather than erythrocytosis 1, 2

Diagnostic Approach

  • The European Hematology Association recommends screening for secondary causes of erythrocytosis that may coexist with HHT, including pulmonary arteriovenous malformations (PAVMs) causing chronic hypoxemia 3
  • Evaluation for polycythemia vera or other primary myeloproliferative disorders that are coincidentally present is necessary 1
  • The American College of Cardiology suggests assessing for obstructive sleep apnea, smoking, or high-altitude exposure as contributing factors is not recommended due to lack of citation, instead, focus on PAVMs and hepatic AVMs 3

Screening Protocol

  • The American Thoracic Society recommends contrast echocardiography or chest CT to detect pulmonary AVMs that may be causing hypoxemia-driven erythrocytosis 3
  • Doppler ultrasonography is recommended as first-line imaging for hepatic AVM assessment 1, 3
  • MRI of the brain is suggested to evaluate for cerebral vascular malformations 3
  • The American Gastroenterological Association advises against liver biopsy due to catastrophic hemorrhage risk 1, 3

Management Algorithm

  • If pulmonary AVMs are identified, percutaneous transcatheter embolization should be performed regardless of feeding artery size due to paradoxical embolism risk and potential for stroke or cerebral abscess 3
  • If no secondary cause is found, referral to hematology for evaluation of primary polycythemia, including JAK2 mutation testing and bone marrow evaluation if indicated, is recommended 1

Anticoagulation Considerations

  • The International Society on Thrombosis and Haemostasis notes that anticoagulation is not an absolute contraindication in HHT despite bleeding risks 1, 4
  • Heparin agents and vitamin K antagonists are preferred over direct oral anticoagulants due to better tolerability and lower bleeding risk in HHT 4, 5
  • Dual antiplatelet therapy and combination antiplatelet/anticoagulation therapy should be avoided wherever possible 1, 4
  • Left atrial appendage closure may be considered for atrial fibrillation in patients who cannot tolerate anticoagulation 1

Monitoring and Follow-Up

  • Baseline iron studies, ferritin, and transferrin saturation should be established even in the presence of erythrocytosis, as HHT patients may transition to iron deficiency if bleeding worsens 1, 2
  • Hemoglobin and hematocrit should be reassessed at 1-month intervals to detect evolution toward anemia, which would indicate progression of typical HHT bleeding manifestations 1